The prevalence of extramedullary acute myeloid leukemia detected by 18FDG-PET/CT: final results from the Prospective PETAML Trial.
Extramedullary disease in patients with acute myeloid leukemia is a known phenomenon. Since the prevalence of extramedullary acute myeloid leukemia has so far been only clinically determined on examination, we performed a prospective study in patients with acute myeloid leukemia. The goal of this prospective study was to determine the prevalence of metabolically active extramedullary acute myeloid leukemia using total body 18FDG-PET/CT imaging at diagnosis prior to initiation of therapy. In order, to define the dynamics of extramedullary acute myeloid leukemia throughout treatment, PET-positive patients underwent a second 18FDG-PET/CT imaging series during follow-up by the time of remission assessment. Findings: A total of 93 patients with acute myeloid leukemia underwent 18FDG-PET/CT scans at diagnosis. The prevalence of PET-positive extramedullary acute myeloid leukemia was 19% in our study with a total of 65 EM AML manifestations and a median number of two extramedullary manifestations per patient (range, 1-12) with a median SUVmax of 6.1 (range, 2-51.4), respectively. When adding those three patients with histologically confirmed extramedullary acute myeloid leukemia who were 18FDG-PET/CT negative in the 18FDG-PET/CT at diagnosis, the combined prevalence for extramedullary acute myeloid leukemia in this study was 22%, resulting in a sensitivity and specificity of 77% and 97%, respectively. Importantly, 60% (6 of 10) patients with histologically confirmed extramedullary acute myeloid leukemia still had active extramedullary disease in their follow-up 18FDG-PET/CT. 18FDG-PET/CT reveals a high prevalence of metabolically active extramedullary disease in acute myeloid leukemia patients. Metabolic activity in extramedullary acute myeloid leukemia may persist even beyond the time-point of hematologic remission, a finding that merits further prospective investigation with respect to its prognostic relevance. This trial is registered at www.clinicaltrials.gov as #NCT01278069.